Fracture in clinical studies of tofacitinib in rheumatoid arthritis

Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk in tofacitinib RA clinical trials. Design: Post hoc analysis. Methods: We analyzed pooled data of phase I/II/III and long-term extension stud...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic advances in musculoskeletal disease Vol. 14; p. 1759720X221142346
Main Authors Hansen, Karen E., Mortezavi, Mahta, Nagy, Edward, Wang, Cunshan, Connell, Carol A., Radi, Zaher, Litman, Heather J., Adami, Giovanni, Rossini, Maurizio
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.01.2022
SAGE PUBLICATIONS, INC
SAGE Publishing
Subjects
Fractures
Musculoskeletal diseases
Original Research
Osteoporosis
Rheumatoid arthritis
Surveillance
JAK inhibitor
osteoporosis
rheumatoid arthritistofacitinib
fracture
Online AccessGet full text

Cover

Abstract Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk in tofacitinib RA clinical trials. Design: Post hoc analysis. Methods: We analyzed pooled data of phase I/II/III and long-term extension studies (‘P123LTE cohort’), pooled data of placebo-controlled portions of phase III studies (phase III placebo-controlled cohort), and data from ORAL Surveillance [phase IIIb/IV randomized, open-label trial evaluating tofacitinib 5/10 mg twice daily (BID) vs tumor necrosis factor inhibitor (TNFi) in patients ⩾ 50 years with ⩾ 1 additional cardiovascular risk factor]. Results: In the phase III placebo-controlled cohort, incidence rates (IRs) [95% confidence interval (CI)] of fracture were 2.11 (1.09–3.68), 2.56 (1.23–4.71), and 4.43 (1.78–9.12) per 100 patient-years (PYs) for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively [tofacitinib 5 mg BID vs placebo: hazard ratio (HR) (95% CI) = 0.55(0.18–1.65); tofacitinib 10 mg BID vs placebo: HR (95% CI) = 0.72 (0.26–2.01)]. In P123LTE, IRs (95% CI) were 2.62 (2.29–2.99) and 2.26 (2.02–2.52) per 100 PY for average tofacitinib 5 and 10 mg BID, respectively. In ORAL Surveillance, IRs (95% CI) were 2.79 (2.34–3.30), 2.87 (2.40–3.40), and 2.27 (1.87–2.74) per 100 PY for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and TNFi, respectively. In ORAL Surveillance, the risk of fracture was numerically higher than TNFi for tofacitinib 5 mg BID [HR (95% CI) = 1.23 (0.96–1.58)] and tofacitinib 10 mg BID [HR (95% CI) = 1.26 (0.97–1.62)]. In ORAL Surveillance, independent predictors of all and osteoporotic fractures with tofacitinib or TNFi included age ⩾ 65, female sex, history of fracture/osteoporosis, and baseline oral corticosteroid use. Conclusion: This post hoc analysis showed numerically lower fracture risk with tofacitinib versus placebo and numerically greater risk versus TNFi. We did not identify any tofacitinib-specific predictors of fractures, and predictors of fracture were generally aligned with prior literature in the general population and patients with RA. Patients with fracture risk factors should be adequately monitored and treated. Clinical trial registration: NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02187055, NCT02831855, NCT00413699, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT00661661, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT01262118, NCT01484561, NCT02281552, NCT02147587, NCT02092467
AbstractList Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk in tofacitinib RA clinical trials. Design: Post hoc analysis. Methods: We analyzed pooled data of phase I/II/III and long-term extension studies (‘ P123LTE cohort’), pooled data of placebo-controlled portions of phase III studies ( phase III placebo-controlled cohort), and data from ORAL Surveillance [phase IIIb/IV randomized, open-label trial evaluating tofacitinib 5/10 mg twice daily (BID) vs tumor necrosis factor inhibitor (TNFi) in patients ⩾ 50 years with ⩾ 1 additional cardiovascular risk factor]. Results: In the phase III placebo-controlled cohort, incidence rates (IRs) [95% confidence interval (CI)] of fracture were 2.11 (1.09–3.68), 2.56 (1.23–4.71), and 4.43 (1.78–9.12) per 100 patient-years (PYs) for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively [tofacitinib 5 mg BID vs placebo: hazard ratio (HR) (95% CI) = 0.55(0.18–1.65); tofacitinib 10 mg BID vs placebo: HR (95% CI) = 0.72 (0.26–2.01)]. In P123LTE , IRs (95% CI) were 2.62 (2.29–2.99) and 2.26 (2.02–2.52) per 100 PY for average tofacitinib 5 and 10 mg BID, respectively. In ORAL Surveillance, IRs (95% CI) were 2.79 (2.34–3.30), 2.87 (2.40–3.40), and 2.27 (1.87–2.74) per 100 PY for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and TNFi, respectively. In ORAL Surveillance, the risk of fracture was numerically higher than TNFi for tofacitinib 5 mg BID [HR (95% CI) = 1.23 (0.96–1.58)] and tofacitinib 10 mg BID [HR (95% CI) = 1.26 (0.97–1.62)]. In ORAL Surveillance, independent predictors of all and osteoporotic fractures with tofacitinib or TNFi included age ⩾ 65, female sex, history of fracture/osteoporosis, and baseline oral corticosteroid use. Conclusion: This post hoc analysis showed numerically lower fracture risk with tofacitinib versus placebo and numerically greater risk versus TNFi. We did not identify any tofacitinib-specific predictors of fractures, and predictors of fracture were generally aligned with prior literature in the general population and patients with RA. Patients with fracture risk factors should be adequately monitored and treated. Clinical trial registration: NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02187055, NCT02831855, NCT00413699, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT00661661, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT01262118, NCT01484561, NCT02281552, NCT02147587, NCT02092467
Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA).BackgroundPreclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA).To assess fracture risk in tofacitinib RA clinical trials.ObjectiveTo assess fracture risk in tofacitinib RA clinical trials.Post hoc analysis.DesignPost hoc analysis.We analyzed pooled data of phase I/II/III and long-term extension studies ('P123LTE cohort'), pooled data of placebo-controlled portions of phase III studies (phase III placebo-controlled cohort), and data from ORAL Surveillance [phase IIIb/IV randomized, open-label trial evaluating tofacitinib 5/10 mg twice daily (BID) vs tumor necrosis factor inhibitor (TNFi) in patients ⩾ 50 years with ⩾ 1 additional cardiovascular risk factor].MethodsWe analyzed pooled data of phase I/II/III and long-term extension studies ('P123LTE cohort'), pooled data of placebo-controlled portions of phase III studies (phase III placebo-controlled cohort), and data from ORAL Surveillance [phase IIIb/IV randomized, open-label trial evaluating tofacitinib 5/10 mg twice daily (BID) vs tumor necrosis factor inhibitor (TNFi) in patients ⩾ 50 years with ⩾ 1 additional cardiovascular risk factor].In the phase III placebo-controlled cohort, incidence rates (IRs) [95% confidence interval (CI)] of fracture were 2.11 (1.09-3.68), 2.56 (1.23-4.71), and 4.43 (1.78-9.12) per 100 patient-years (PYs) for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively [tofacitinib 5 mg BID vs placebo: hazard ratio (HR) (95% CI) = 0.55(0.18-1.65); tofacitinib 10 mg BID vs placebo: HR (95% CI) = 0.72 (0.26-2.01)]. In P123LTE, IRs (95% CI) were 2.62 (2.29-2.99) and 2.26 (2.02-2.52) per 100 PY for average tofacitinib 5 and 10 mg BID, respectively. In ORAL Surveillance, IRs (95% CI) were 2.79 (2.34-3.30), 2.87 (2.40-3.40), and 2.27 (1.87-2.74) per 100 PY for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and TNFi, respectively. In ORAL Surveillance, the risk of fracture was numerically higher than TNFi for tofacitinib 5 mg BID [HR (95% CI) = 1.23 (0.96-1.58)] and tofacitinib 10 mg BID [HR (95% CI) = 1.26 (0.97-1.62)]. In ORAL Surveillance, independent predictors of all and osteoporotic fractures with tofacitinib or TNFi included age ⩾ 65, female sex, history of fracture/osteoporosis, and baseline oral corticosteroid use.ResultsIn the phase III placebo-controlled cohort, incidence rates (IRs) [95% confidence interval (CI)] of fracture were 2.11 (1.09-3.68), 2.56 (1.23-4.71), and 4.43 (1.78-9.12) per 100 patient-years (PYs) for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively [tofacitinib 5 mg BID vs placebo: hazard ratio (HR) (95% CI) = 0.55(0.18-1.65); tofacitinib 10 mg BID vs placebo: HR (95% CI) = 0.72 (0.26-2.01)]. In P123LTE, IRs (95% CI) were 2.62 (2.29-2.99) and 2.26 (2.02-2.52) per 100 PY for average tofacitinib 5 and 10 mg BID, respectively. In ORAL Surveillance, IRs (95% CI) were 2.79 (2.34-3.30), 2.87 (2.40-3.40), and 2.27 (1.87-2.74) per 100 PY for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and TNFi, respectively. In ORAL Surveillance, the risk of fracture was numerically higher than TNFi for tofacitinib 5 mg BID [HR (95% CI) = 1.23 (0.96-1.58)] and tofacitinib 10 mg BID [HR (95% CI) = 1.26 (0.97-1.62)]. In ORAL Surveillance, independent predictors of all and osteoporotic fractures with tofacitinib or TNFi included age ⩾ 65, female sex, history of fracture/osteoporosis, and baseline oral corticosteroid use.This post hoc analysis showed numerically lower fracture risk with tofacitinib versus placebo and numerically greater risk versus TNFi. We did not identify any tofacitinib-specific predictors of fractures, and predictors of fracture were generally aligned with prior literature in the general population and patients with RA. Patients with fracture risk factors should be adequately monitored and treated.ConclusionThis post hoc analysis showed numerically lower fracture risk with tofacitinib versus placebo and numerically greater risk versus TNFi. We did not identify any tofacitinib-specific predictors of fractures, and predictors of fracture were generally aligned with prior literature in the general population and patients with RA. Patients with fracture risk factors should be adequately monitored and treated.NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02187055, NCT02831855, NCT00413699, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT00661661, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT01262118, NCT01484561, NCT02281552, NCT02147587, NCT02092467.Clinical trial registrationNCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02187055, NCT02831855, NCT00413699, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT00661661, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT01262118, NCT01484561, NCT02281552, NCT02147587, NCT02092467.
Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). To assess fracture risk in tofacitinib RA clinical trials. Post hoc analysis. We analyzed pooled data of phase I/II/III and long-term extension studies (' cohort'), pooled data of placebo-controlled portions of phase III studies ( cohort), and data from ORAL Surveillance [phase IIIb/IV randomized, open-label trial evaluating tofacitinib 5/10 mg twice daily (BID) tumor necrosis factor inhibitor (TNFi) in patients ⩾ 50 years with ⩾ 1 additional cardiovascular risk factor]. In the cohort, incidence rates (IRs) [95% confidence interval (CI)] of fracture were 2.11 (1.09-3.68), 2.56 (1.23-4.71), and 4.43 (1.78-9.12) per 100 patient-years (PYs) for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively [tofacitinib 5 mg BID placebo: hazard ratio (HR) (95% CI) = 0.55(0.18-1.65); tofacitinib 10 mg BID placebo: HR (95% CI) = 0.72 (0.26-2.01)]. In , IRs (95% CI) were 2.62 (2.29-2.99) and 2.26 (2.02-2.52) per 100 PY for average tofacitinib 5 and 10 mg BID, respectively. In ORAL Surveillance, IRs (95% CI) were 2.79 (2.34-3.30), 2.87 (2.40-3.40), and 2.27 (1.87-2.74) per 100 PY for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and TNFi, respectively. In ORAL Surveillance, the risk of fracture was numerically higher than TNFi for tofacitinib 5 mg BID [HR (95% CI) = 1.23 (0.96-1.58)] and tofacitinib 10 mg BID [HR (95% CI) = 1.26 (0.97-1.62)]. In ORAL Surveillance, independent predictors of all and osteoporotic fractures with tofacitinib or TNFi included age ⩾ 65, female sex, history of fracture/osteoporosis, and baseline oral corticosteroid use. This post hoc analysis showed numerically lower fracture risk with tofacitinib placebo and numerically greater risk TNFi. We did not identify any tofacitinib-specific predictors of fractures, and predictors of fracture were generally aligned with prior literature in the general population and patients with RA. Patients with fracture risk factors should be adequately monitored and treated. NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02187055, NCT02831855, NCT00413699, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT00661661, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT01262118, NCT01484561, NCT02281552, NCT02147587, NCT02092467.
Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk in tofacitinib RA clinical trials. Design: Post hoc analysis. Methods: We analyzed pooled data of phase I/II/III and long-term extension studies (‘P123LTE cohort’), pooled data of placebo-controlled portions of phase III studies (phase III placebo-controlled cohort), and data from ORAL Surveillance [phase IIIb/IV randomized, open-label trial evaluating tofacitinib 5/10 mg twice daily (BID) vs tumor necrosis factor inhibitor (TNFi) in patients ⩾ 50 years with ⩾ 1 additional cardiovascular risk factor]. Results: In the phase III placebo-controlled cohort, incidence rates (IRs) [95% confidence interval (CI)] of fracture were 2.11 (1.09–3.68), 2.56 (1.23–4.71), and 4.43 (1.78–9.12) per 100 patient-years (PYs) for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively [tofacitinib 5 mg BID vs placebo: hazard ratio (HR) (95% CI) = 0.55(0.18–1.65); tofacitinib 10 mg BID vs placebo: HR (95% CI) = 0.72 (0.26–2.01)]. In P123LTE, IRs (95% CI) were 2.62 (2.29–2.99) and 2.26 (2.02–2.52) per 100 PY for average tofacitinib 5 and 10 mg BID, respectively. In ORAL Surveillance, IRs (95% CI) were 2.79 (2.34–3.30), 2.87 (2.40–3.40), and 2.27 (1.87–2.74) per 100 PY for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and TNFi, respectively. In ORAL Surveillance, the risk of fracture was numerically higher than TNFi for tofacitinib 5 mg BID [HR (95% CI) = 1.23 (0.96–1.58)] and tofacitinib 10 mg BID [HR (95% CI) = 1.26 (0.97–1.62)]. In ORAL Surveillance, independent predictors of all and osteoporotic fractures with tofacitinib or TNFi included age ⩾ 65, female sex, history of fracture/osteoporosis, and baseline oral corticosteroid use. Conclusion: This post hoc analysis showed numerically lower fracture risk with tofacitinib versus placebo and numerically greater risk versus TNFi. We did not identify any tofacitinib-specific predictors of fractures, and predictors of fracture were generally aligned with prior literature in the general population and patients with RA. Patients with fracture risk factors should be adequately monitored and treated. Clinical trial registration: NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02187055, NCT02831855, NCT00413699, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT00661661, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT01262118, NCT01484561, NCT02281552, NCT02147587, NCT02092467
Author Hansen, Karen E.
Mortezavi, Mahta
Wang, Cunshan
Litman, Heather J.
Nagy, Edward
Adami, Giovanni
Radi, Zaher
Rossini, Maurizio
Connell, Carol A.
Author_xml – sequence: 1
  givenname: Karen E.
  surname: Hansen
  fullname: Hansen, Karen E.
  organization: Division of Rheumatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
– sequence: 2
  givenname: Mahta
  surname: Mortezavi
  fullname: Mortezavi, Mahta
  email: mahta.mortezavi@pfizer.com
  organization: Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA
– sequence: 3
  givenname: Edward
  surname: Nagy
  fullname: Nagy, Edward
  organization: Pfizer Ltd, Tadworth, UK
– sequence: 4
  givenname: Cunshan
  surname: Wang
  fullname: Wang, Cunshan
  organization: Pfizer Inc., Groton, CT, USA
– sequence: 5
  givenname: Carol A.
  surname: Connell
  fullname: Connell, Carol A.
  organization: Pfizer Inc., Groton, CT, USA
– sequence: 6
  givenname: Zaher
  surname: Radi
  fullname: Radi, Zaher
  organization: Pfizer Inc., Cambridge, MA, USA
– sequence: 7
  givenname: Heather J.
  surname: Litman
  fullname: Litman, Heather J.
  organization: CorEvitas, LLC, Waltham, MA, USA
– sequence: 8
  givenname: Giovanni
  surname: Adami
  fullname: Adami, Giovanni
  organization: Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
– sequence: 9
  givenname: Maurizio
  orcidid: 0000-0001-9692-2293
  surname: Rossini
  fullname: Rossini, Maurizio
  organization: Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36601090$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1rFDEUhoNU7If-AG9kwBtvtubk60xuBFlsLRS8UehdyGQyu1lmJzXJFPz3Zrt1tRW9SjjneV_e5JxTcjTFyRPyGug5AOJ7QKmR0RvGAATjQj0jJ7vaAhm0R4c7vTkmpzlvKFWaanhBjrlSFKimJ2R5kawrc_JNmBo3hik4Oza5zH3wuYlDU-JgXSi10e2QtPbz1pYY-samsk61k1-S54Mds3_1cJ6Rbxefvi4_L66_XF4tP14vnOSsLFChBymFatGKDi3lHUNUqqed88iZc8ICcge8t3ZwklGGXA9SyE6howM_I1d73z7ajblNYWvTDxNtMPeFmFamZgpu9AZ63aEEofq-FWrwtmsBOoHUq0G4VlevD3uv27nb-t75qSQ7PjJ93JnC2qzindEtVVxBNXj3YJDi99nnYrYhOz-OdvJxzoahqjNqNciKvn2CbuKcpvpVlZKtRIl6Z_jmz0SHKL9mVQHYAy7FnJMfDghQs9sH89c-VA0-0dRZ2hLi7lFh_K_yfK_MduV_B_634CcWe8T9
CitedBy_id crossref_primary_10_1016_j_semarthrit_2023_152345
crossref_primary_10_12968_hmed_2024_0341
crossref_primary_10_2174_0115733971288433240408062359
crossref_primary_10_1007_s40520_023_02432_9
crossref_primary_10_1007_s40744_023_00575_9
crossref_primary_10_1186_s41927_024_00414_6
crossref_primary_10_1016_j_ard_2025_01_024
Cites_doi 10.1136/annrheumdis-2019-215328
10.1007/s00198-010-1192-7
10.1002/jbmr.449
10.1007/s00198-004-1640-3
10.1007/s00223-014-9855-6
10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y
10.1080/14656566.2020.1787381
10.1002/art.34649
10.1001/jama.2009.1738
10.1126/scitranslmed.aay4447
10.1093/rheumatology/kex258
10.1136/bmjopen-2018-024951
10.1136/annrheumdis-2019-215714
10.1007/s00198-021-05871-0
10.1093/rheumatology/keq084
10.1371/journal.pone.0181126
10.1001/archinte.159.15.1750
10.1001/jama.293.17.2102
10.3389/fendo.2019.00817
10.3109/15476910903453296
10.1186/s13075-016-1116-9
10.1007/s00198-021-05824-7
10.3109/14397595.2015.1004276
10.1186/ar3107
10.1093/rheumatology/keu162
10.1002/acr.21761
10.1056/NEJMoa2109927
10.1210/edrv.23.1.0456
10.3389/fimmu.2014.00511
10.1007/s11926-019-0836-7
10.1210/clinem/dgab690
10.3389/fmed.2020.601618
10.1007/s00198-015-3168-0
10.1001/archinte.164.2.146
10.1136/annrheumdis-2020-218758
10.1136/annrheumdis-2020-eular.5998
10.1016/j.jbspin.2014.10.015
10.1007/s001980170112
10.1016/j.bone.2021.116137
10.1093/rheumatology/kez655
10.1111/j.1756-185X.2012.01729.x
10.1136/rmdopen-2019-001042
10.1007/s00198-007-0543-5
10.1007/s00198-021-05862-1
10.1136/thx.2011.160028
10.3390/ijms21030865
10.3899/jrheum.101196
10.1681/ASN.2005111194
10.3727/096368914X678319
ContentType Journal Article
Copyright The Author(s), 2022
The Author(s), 2022.
The Author(s), 2022. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s), 2022 2022 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s), 2022
– notice: The Author(s), 2022.
– notice: The Author(s), 2022. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s), 2022 2022 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
AAYXX
CITATION
NPM
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1177/1759720X221142346
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: WRHA-DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1759-7218
ExternalDocumentID oai_doaj_org_article_1d9b75146dd846feab811b470e6f4c89
PMC9806361
36601090
10_1177_1759720X221142346
10.1177_1759720X221142346
Genre Journal Article
GrantInformation_xml – fundername: Pfizer
  funderid: https://doi.org/10.13039/100004319
– fundername: ;
GroupedDBID ---
-TM
.WF
01A
0R~
4.4
53G
54M
7RV
7X7
8FI
8FJ
AABMB
AADUE
AAKDD
AAQDB
AARDL
AARIX
AASGM
ABAWP
ABEIX
ABFWQ
ABJIS
ABKRH
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACOFE
ACROE
ACRPL
ADBBV
ADEBD
ADNMO
ADOGD
ADYCS
ADZZY
AEFTW
AEQLS
AERKM
AEUHG
AEWDL
AEXNY
AFCOW
AFEET
AFKRA
AFKRG
AFRWT
AFUIA
AFWMB
AGNHF
AGQPQ
AHHFK
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
ASPBG
AUTPY
AVWKF
AYAKG
AZFZN
B8M
BAWUL
BDDNI
BENPR
BKEYQ
BKSCU
BPHCQ
BSEHC
BVXVI
CAG
CCPQU
CDWPY
CFDXU
COF
DC-
DC.
DIK
DOPDO
EBS
EJD
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GX1
H13
HF~
HMCUK
HVGLF
HYE
HZ~
J8X
K.F
N9A
NAPCQ
O9-
OK1
P.B
PHGZM
PHGZT
PIMPY
PQQKQ
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
CITATION
31X
AADTT
AATBZ
ACGZU
ACSBE
ACSIQ
ACTQU
ACUIR
AEUIJ
AEWHI
B8Z
DV7
M4V
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PPXIY
PQEST
PQUKI
PRINS
PUEGO
7X8
5PM
ID FETCH-LOGICAL-c532t-767e1554687a4b7a03b27766d0bce732cc4a173c13daafc5202739f545b67c0f3
IEDL.DBID 7X7
ISSN 1759-720X
IngestDate Wed Aug 27 01:32:16 EDT 2025
Thu Aug 21 18:37:57 EDT 2025
Fri Jul 11 09:46:01 EDT 2025
Sat Aug 23 14:32:50 EDT 2025
Wed Feb 19 02:24:25 EST 2025
Thu Apr 24 23:11:11 EDT 2025
Tue Jul 01 05:25:36 EDT 2025
Tue Jun 17 22:29:28 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords JAK inhibitor
osteoporosis
rheumatoid arthritistofacitinib
fracture
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
The Author(s), 2022.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c532t-767e1554687a4b7a03b27766d0bce732cc4a173c13daafc5202739f545b67c0f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-9692-2293
OpenAccessLink https://www.proquest.com/docview/2758575791?pq-origsite=%requestingapplication%
PMID 36601090
PQID 2758575791
PQPubID 4450846
ParticipantIDs doaj_primary_oai_doaj_org_article_1d9b75146dd846feab811b470e6f4c89
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9806361
proquest_miscellaneous_2761178915
proquest_journals_2758575791
pubmed_primary_36601090
crossref_primary_10_1177_1759720X221142346
crossref_citationtrail_10_1177_1759720X221142346
sage_journals_10_1177_1759720X221142346
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-01-01
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – month: 01
  year: 2022
  text: 2022-01-01
  day: 01
PublicationDecade 2020
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: London
– name: Sage UK: London, England
PublicationTitle Therapeutic advances in musculoskeletal disease
PublicationTitleAlternate Ther Adv Musculoskelet Dis
PublicationYear 2022
Publisher SAGE Publications
SAGE PUBLICATIONS, INC
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: SAGE PUBLICATIONS, INC
– name: SAGE Publishing
References LaBranche, Jesson, Radi 2012; 64
Chen, Hsu, Yu 2020; 59
Erwin, Enki, Woolf 2021; 32
Freedberg, Haynes, Denburg 2015; 26
Ogdie, de Vlam, McInnes 2020; 6
Batteux, Bennis, Bodeau 2021; 153
Ishida, Furuya, Inoue 2015; 25
El Maghraoui, Rezqi, Mounach 2010; 49
Hsu, Chang 2014; 23
Lee, Park, Park 2012; 15
Nickolas, McMahon, Shane 2006; 17
Leutner, Matzhold, Bellach 2019; 78
Kanis, Oden, Johnell 2001; 12
Edwards, Williams 2010; 21
Cauley, Danielson, Boudreau 2011; 26
Clynes, Jameson, Prieto-Alhambra 2019; 10
Leveille, Jones, Kiely 2009; 302
Kanis, Johnell, Oden 2008; 19
Kim, Schneeweiss, Liu 2010; 12
Ozen, Pedro, Wolfe 2019; 78
ElKassar, Gress 2010; 7
Ytterberg, Bhatt, Mikuls 2022; 386
Duca, Spinelli, Ceccarelli 2020; 79
Pfeilschifter, Koditz, Pfohl 2002; 23
Adam, Simon, Steffen 2020; 12
Bugatti, Bogliolo, Vitolo 2016; 18
Guanabens, Olmos, Hernandez 2021; 32
Loke, Cavallazzi, Singh 2011; 66
Wright, Lisse, Walitt 2011; 38
Gaber, Brinkman, Pienczikowski 2020; 21
Hauser, Riches, Wilson 2014; 53
Hamar, Szekanecz, Pusztai 2021; 32
Ding, Heller, Ahern 2014; 94
Caraballo, Heit, Atkinson 1999; 159
Haugeberg, Uhlig, Falch 2000; 43
Briot, Rouanet, Schaeverbeke 2015; 82
Llorente, Garcia-Castaneda, Valero 2020; 7
Murakami, Kobayashi, Uehara 2017; 12
Bauer, Mundy, Jamal 2004; 164
Kanis, Johnell, Oden 2005; 16
Cauley, Lui, Ensrud 2005; 293
Vidal, Cascao, Finnila 2018; 57
Akyea, McKeever, Gibson 2019; 9
Michaelsson, Baron, Farahmand 1998; 316
Raterman, Bultink, Lems 2020; 21
Avouac, Koumakis, Toth 2012; 64
Shieh, Ruppert, Greendale 2022; 107
Adami, Saag 2019; 21
Abtahi, Driessen, Burden 2021; 80
Walsh, Choi 2014; 5
bibr14-1759720X221142346
bibr27-1759720X221142346
bibr4-1759720X221142346
bibr21-1759720X221142346
bibr47-1759720X221142346
bibr41-1759720X221142346
bibr34-1759720X221142346
bibr22-1759720X221142346
bibr28-1759720X221142346
bibr15-1759720X221142346
bibr42-1759720X221142346
bibr48-1759720X221142346
bibr43-1759720X221142346
bibr8-1759720X221142346
bibr33-1759720X221142346
bibr2-1759720X221142346
bibr49-1759720X221142346
bibr3-1759720X221142346
bibr39-1759720X221142346
bibr29-1759720X221142346
bibr19-1759720X221142346
bibr9-1759720X221142346
bibr23-1759720X221142346
bibr13-1759720X221142346
bibr37-1759720X221142346
bibr1-1759720X221142346
bibr44-1759720X221142346
bibr11-1759720X221142346
bibr17-1759720X221142346
bibr7-1759720X221142346
bibr31-1759720X221142346
bibr24-1759720X221142346
bibr51-1759720X221142346
bibr45-1759720X221142346
bibr25-1759720X221142346
bibr32-1759720X221142346
bibr12-1759720X221142346
bibr18-1759720X221142346
bibr52-1759720X221142346
bibr38-1759720X221142346
bibr30-1759720X221142346
bibr40-1759720X221142346
bibr5-1759720X221142346
bibr36-1759720X221142346
bibr46-1759720X221142346
bibr6-1759720X221142346
bibr16-1759720X221142346
bibr26-1759720X221142346
bibr50-1759720X221142346
Michaelsson K (bibr35-1759720X221142346) 1998; 316
bibr10-1759720X221142346
bibr20-1759720X221142346
References_xml – volume: 16
  start-page: 155
  year: 2005
  end-page: 162
  article-title: Smoking and fracture risk: a meta-analysis
  publication-title: Osteoporos Int
– volume: 32
  start-page: 1621
  year: 2021
  end-page: 1629
  article-title: Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis
  publication-title: Osteoporos Int
– volume: 94
  start-page: 597
  year: 2014
  end-page: 607
  article-title: The relationship between proton pump inhibitor adherence and fracture risk in the elderly
  publication-title: Calcif Tissue Int
– volume: 6
  year: 2020
  article-title: Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
  publication-title: RMD Open
– volume: 32
  start-page: 1333
  year: 2021
  end-page: 1342
  article-title: Vertebral fractures are increased in rheumatoid arthritis despite recent therapeutic advances: a case-control study
  publication-title: Osteoporos Int
– volume: 64
  start-page: 1871
  year: 2012
  end-page: 1878
  article-title: Increased risk of osteoporosis and fracture in women with systemic sclerosis: a comparative study with rheumatoid arthritis
  publication-title: Arthritis Care Res
– volume: 153
  start-page: 116137
  year: 2021
  article-title: Associations between osteoporosis and drug exposure: a post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)
  publication-title: Bone
– volume: 15
  start-page: 289
  year: 2012
  end-page: 296
  article-title: Increased frequency of osteoporosis and BMD below the expected range for age among South Korean women with rheumatoid arthritis
  publication-title: Int J Rheum Dis
– volume: 316
  start-page: 1858
  year: 1998
  end-page: 1863
  article-title: Hormone replacement therapy and risk of hip fracture: population based case-control study
  publication-title: The Swedish Hip Fracture Study Group BMJ
– volume: 78
  start-page: 1041
  year: 2019
  end-page: 1047
  article-title: Medications associated with fracture risk in patients with rheumatoid arthritis
  publication-title: Ann Rheum Dis
– volume: 21
  start-page: 865
  year: 2020
  article-title: Impact of Janus kinase inhibition with tofacitinib on fundamental processes of bone healing
  publication-title: Int J Mol Sci
– volume: 164
  start-page: 146
  year: 2004
  end-page: 152
  article-title: Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials
  publication-title: Arch Intern Med
– volume: 64
  start-page: 3531
  year: 2012
  end-page: 3542
  article-title: JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production
  publication-title: Arthritis Rheum
– volume: 7
  year: 2020
  article-title: Osteoporosis in rheumatoid arthritis: dangerous liaisons
  publication-title: Front Med
– volume: 38
  start-page: 1680
  year: 2011
  end-page: 1688
  article-title: Arthritis increases the risk for fractures – results from the Women’s Health Initiative
  publication-title: J Rheumatol
– volume: 26
  start-page: 2378
  year: 2011
  end-page: 2388
  article-title: Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: the Women’s Health Initiative (WHI)
  publication-title: J Bone Miner Res
– volume: 12
  year: 2017
  article-title: A JAK1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro
  publication-title: PLoS One
– volume: 159
  start-page: 1750
  year: 1999
  end-page: 1756
  article-title: Long-term use of oral anticoagulants and the risk of fracture
  publication-title: Arch Intern Med
– volume: 302
  start-page: 2214
  year: 2009
  end-page: 2221
  article-title: Chronic musculoskeletal pain and the occurrence of falls in an older population
  publication-title: JAMA
– volume: 293
  start-page: 2102
  year: 2005
  end-page: 2108
  article-title: Bone mineral density and the risk of incident nonspinal fractures in black and white women
  publication-title: JAMA
– volume: 80
  start-page: 423
  year: 2021
  end-page: 431
  article-title: Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study
  publication-title: Ann Rheum Dis
– volume: 12
  year: 2010
  article-title: Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis
  publication-title: Arthritis Res Ther
– volume: 21
  start-page: 1725
  year: 2020
  end-page: 1737
  article-title: Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention
  publication-title: Expert Opin Pharmacother
– volume: 66
  start-page: 699
  year: 2011
  end-page: 708
  article-title: Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies
  publication-title: Thorax
– volume: 43
  start-page: 522
  year: 2000
  end-page: 530
  article-title: Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register
  publication-title: Arthritis Rheum
– volume: 18
  start-page: 226
  year: 2016
  article-title: Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
  publication-title: Arthritis Res Ther
– volume: 26
  start-page: 2501
  year: 2015
  end-page: 2507
  article-title: Use of proton pump inhibitors is associated with fractures in young adults: a population-based study
  publication-title: Osteoporos Int
– volume: 21
  start-page: 34
  year: 2019
  article-title: Osteoporosis pathophysiology, epidemiology, and screening in rheumatoid arthritis
  publication-title: Curr Rheumatol Rep
– volume: 79
  start-page: 641
  year: 2020
  end-page: 642
  article-title: Steroid-sparing effect of JAK inhibitors in rheumatoid arthritis patients followed up in a real life setting
  publication-title: Ann Rheum Dis
– volume: 12
  year: 2020
  article-title: JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function
  publication-title: Sci Transl Med
– volume: 12
  start-page: 417
  year: 2001
  end-page: 427
  article-title: The burden of osteoporotic fractures: a method for setting intervention thresholds
  publication-title: Osteoporos Int
– volume: 19
  start-page: 385
  year: 2008
  end-page: 397
  article-title: FRAX and the assessment of fracture probability in men and women from the UK
  publication-title: Osteoporos Int
– volume: 21
  start-page: 1287
  year: 2010
  end-page: 1293
  article-title: The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis
  publication-title: Osteoporos Int
– volume: 25
  start-page: 373
  year: 2015
  end-page: 378
  article-title: Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: results from a large prospective observational cohort study
  publication-title: Mod Rheumatol
– volume: 49
  start-page: 1303
  year: 2010
  end-page: 1310
  article-title: Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis using vertebral fracture assessment
  publication-title: Rheumatology
– volume: 386
  start-page: 316
  year: 2022
  end-page: 326
  article-title: Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis
  publication-title: N Engl J Med
– volume: 59
  start-page: 2471
  year: 2020
  end-page: 2480
  article-title: The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis
  publication-title: Rheumatology
– volume: 32
  start-page: 1651
  year: 2021
  end-page: 1659
  article-title: Younger people with rheumatoid arthritis are at increased risk of fracture even before age 50 years: a population-based cohort study
  publication-title: Osteoporos Int
– volume: 7
  start-page: 1
  year: 2010
  end-page: 7
  article-title: An overview of IL-7 biology and its use in immunotherapy
  publication-title: J Immunotoxicol
– volume: 9
  year: 2019
  article-title: Predicting fracture risk in patients with chronic obstructive pulmonary disease: a UK-based population-based cohort study
  publication-title: BMJ Open
– volume: 53
  start-page: 1759
  year: 2014
  end-page: 1766
  article-title: Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis
  publication-title: Rheumatology
– volume: 10
  start-page: 817
  year: 2019
  article-title: Impact of rheumatoid arthritis and its management on falls, fracture and bone mineral density in UK biobank
  publication-title: Front Endocrinol
– volume: 78
  start-page: 1706
  year: 2019
  end-page: 1711
  article-title: Diagnosis of osteoporosis in statin-treated patients is dose-dependent
  publication-title: Ann Rheum Dis
– volume: 5
  start-page: 511
  year: 2014
  article-title: Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond
  publication-title: Front Immunol
– volume: 82
  start-page: 109
  year: 2015
  end-page: 115
  article-title: The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis
  publication-title: Joint Bone Spine
– volume: 107
  year: 2022
  article-title: Associations of age at menopause with postmenopausal bone mineral density and fracture risk in women
  publication-title: J Clin Endocrinol Metab
– volume: 23
  start-page: 90
  year: 2002
  end-page: 119
  article-title: Changes in proinflammatory cytokine activity after menopause
  publication-title: Endocr Rev
– volume: 57
  start-page: 1461
  year: 2018
  end-page: 1471
  article-title: Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model
  publication-title: Rheumatology
– volume: 23
  start-page: 631
  year: 2014
  end-page: 639
  article-title: The therapeutic potential of anti-interleukin-20 monoclonal antibody
  publication-title: Cell Transplant
– volume: 17
  start-page: 3223
  year: 2006
  end-page: 3232
  article-title: Relationship between moderate to severe kidney disease and hip fracture in the United States
  publication-title: J Am Soc Nephrol
– ident: bibr10-1759720X221142346
  doi: 10.1136/annrheumdis-2019-215328
– ident: bibr25-1759720X221142346
  doi: 10.1007/s00198-010-1192-7
– ident: bibr37-1759720X221142346
  doi: 10.1002/jbmr.449
– ident: bibr47-1759720X221142346
  doi: 10.1007/s00198-004-1640-3
– ident: bibr13-1759720X221142346
  doi: 10.1007/s00223-014-9855-6
– ident: bibr3-1759720X221142346
  doi: 10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y
– ident: bibr6-1759720X221142346
  doi: 10.1080/14656566.2020.1787381
– ident: bibr29-1759720X221142346
  doi: 10.1002/art.34649
– ident: bibr42-1759720X221142346
  doi: 10.1001/jama.2009.1738
– ident: bibr22-1759720X221142346
  doi: 10.1126/scitranslmed.aay4447
– ident: bibr20-1759720X221142346
  doi: 10.1093/rheumatology/kex258
– ident: bibr33-1759720X221142346
  doi: 10.1136/bmjopen-2018-024951
– ident: bibr52-1759720X221142346
  doi: 10.1136/annrheumdis-2019-215714
– ident: bibr15-1759720X221142346
  doi: 10.1007/s00198-021-05871-0
– ident: bibr19-1759720X221142346
– ident: bibr9-1759720X221142346
  doi: 10.1093/rheumatology/keq084
– ident: bibr27-1759720X221142346
  doi: 10.1371/journal.pone.0181126
– ident: bibr36-1759720X221142346
  doi: 10.1001/archinte.159.15.1750
– ident: bibr38-1759720X221142346
  doi: 10.1001/jama.293.17.2102
– ident: bibr39-1759720X221142346
  doi: 10.3389/fendo.2019.00817
– ident: bibr23-1759720X221142346
  doi: 10.3109/15476910903453296
– ident: bibr50-1759720X221142346
  doi: 10.1186/s13075-016-1116-9
– ident: bibr7-1759720X221142346
  doi: 10.1007/s00198-021-05824-7
– ident: bibr8-1759720X221142346
  doi: 10.3109/14397595.2015.1004276
– ident: bibr4-1759720X221142346
  doi: 10.1186/ar3107
– ident: bibr17-1759720X221142346
  doi: 10.1093/rheumatology/keu162
– ident: bibr40-1759720X221142346
  doi: 10.1002/acr.21761
– ident: bibr31-1759720X221142346
  doi: 10.1056/NEJMoa2109927
– ident: bibr45-1759720X221142346
  doi: 10.1210/edrv.23.1.0456
– ident: bibr18-1759720X221142346
– ident: bibr24-1759720X221142346
  doi: 10.3389/fimmu.2014.00511
– ident: bibr43-1759720X221142346
  doi: 10.1007/s11926-019-0836-7
– volume: 316
  start-page: 1858
  year: 1998
  ident: bibr35-1759720X221142346
  publication-title: The Swedish Hip Fracture Study Group
– ident: bibr49-1759720X221142346
  doi: 10.1210/clinem/dgab690
– ident: bibr5-1759720X221142346
  doi: 10.3389/fmed.2020.601618
– ident: bibr14-1759720X221142346
  doi: 10.1007/s00198-015-3168-0
– ident: bibr51-1759720X221142346
  doi: 10.1001/archinte.164.2.146
– ident: bibr12-1759720X221142346
  doi: 10.1136/annrheumdis-2020-218758
– ident: bibr44-1759720X221142346
  doi: 10.1136/annrheumdis-2020-eular.5998
– ident: bibr26-1759720X221142346
  doi: 10.1016/j.jbspin.2014.10.015
– ident: bibr32-1759720X221142346
  doi: 10.1007/s001980170112
– ident: bibr30-1759720X221142346
  doi: 10.1016/j.bone.2021.116137
– ident: bibr16-1759720X221142346
  doi: 10.1093/rheumatology/kez655
– ident: bibr2-1759720X221142346
  doi: 10.1111/j.1756-185X.2012.01729.x
– ident: bibr41-1759720X221142346
  doi: 10.1136/rmdopen-2019-001042
– ident: bibr46-1759720X221142346
  doi: 10.1007/s00198-007-0543-5
– ident: bibr11-1759720X221142346
  doi: 10.1007/s00198-021-05862-1
– ident: bibr48-1759720X221142346
  doi: 10.1136/thx.2011.160028
– ident: bibr21-1759720X221142346
  doi: 10.3390/ijms21030865
– ident: bibr1-1759720X221142346
  doi: 10.3899/jrheum.101196
– ident: bibr34-1759720X221142346
  doi: 10.1681/ASN.2005111194
– ident: bibr28-1759720X221142346
  doi: 10.3727/096368914X678319
SSID ssj0069091
Score 2.2770233
Snippet Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk...
Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). To assess fracture risk in tofacitinib RA...
Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk...
Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA).BackgroundPreclinical data suggest that...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1759720X221142346
SubjectTerms Fractures
Musculoskeletal diseases
Original Research
Osteoporosis
Rheumatoid arthritis
Surveillance
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5CDiGX0GfqNi0OFAIBU70sWcc2dAmF9NTA3oye7EKxy8b7_zOSvdtd8uilV2tsD6OR5xtr5hPAZ89ry4S0FboLr4QIqtKchCoKr3VEJ6I-s33-lNe34se8nu8c9ZVqwkZ64NFwX6jXVmFUl95jqIzB2IZSKxQJMgrX5NY9jHmbZGr8BmPKp-m0h5nolTBGasXInLHUOsoT2t2JQpms_zGE-bBQcqfaKweg2Qs4mZBj-XXU-CUchO4VHN1Me-Ov4WqWGp7Wq1Auu3LT8FjejXWCZR_LoY_GLQccsElktQhrhKv90pdohUUmN3oDt7Pvv66uq-mIhMrVnA2VkiokRCAbZYRVhnDLlJLSE-uC4sw5YajijnJvTHR1-tXBdUTYZKVyJPK3cNj1XXgHpfEmEEeCrnnAnJnahljEX67BJ0XpWQFkY7LWTfzh6RiL3y2dKMMfWLmAy-0tf0byjOeEv6V52Aom3ut8Ab2hnbyh_Zc3FHC2mcV2Wox3LUs5kaqVpgWcb4dxGaW9EdOFfp1kJKrVaFoXcDpO-lYTLmWuXy1A7bnDnqr7I91ykam6dYMQUOJ7L5Lj_FXpSSu8_x9W-ADHLHVp5D9FZ3A4rNbhI2KnwX7Ky-QebiQRQw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Sage Journals GOLD Open Access 2024
  dbid: AFRWT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1baxQxFA51C-KLeHdqlREEQRib2ySTJ6nFpQj6IC3u25Cru9DOyHbmwX_fnGxmdWkVX5Mzk0NyTvIl54bQG8dqQ7kwVRQXVnHuZaUY9lXgTqkQhYi4lO3zqzg9558X9WIP9VMsTJ7Bq_fgVhU5Sps1aDe8Rh9lI-NRPPOUpHhBKYSCMi4-jMNlu3nunqpqQAvYp8dLMG1bcIj8VU3hbXfQPpWipjO0fzz_9v1s2rzjXTEV2YMBKhghG0JvHXTnKEsZ_2-DqTe9Lf9wGUun2PwBup_hZ3m8kZeHaM93j9DdL9nA_hidzCFqalz7ctWVU9RkebVxNiz7UA590HY1xA4DJOulHyPm7VeujDK4TBmSnqDz-aezk9Mq11mobM3oUEkhPcAK0UjNjdSYGSqlEA4b6yWj1nJNJLOEOa2DreG9hKkQsZcR0uLAnqJZ13f-OSq10x5b7FXNfLx4E9NgE0GcbeKfgnC0QHiastbmJORQC-OiJTnv-I1ZLtC77Sc_Nxk4_kX8EdZhSwjJs1NDv_7RZl1siVNGRqAonIvoK3htGkIMl9iLwG2jCnQ4rWI7yWNL4WIla6lIgV5vu6MugoFFd74fgUZEthpF6gI92yz6lhMmRHKCLZDcEYcdVnd7utUy5ftWTcSRIo77FgTnN0t_nYWD_6Z8ge5RiOdIb0qHaDasR_8yoqzBvMqacQ03yB5s
  priority: 102
  providerName: SAGE Publications
Title Fracture in clinical studies of tofacitinib in rheumatoid arthritis
URI https://journals.sagepub.com/doi/full/10.1177/1759720X221142346
https://www.ncbi.nlm.nih.gov/pubmed/36601090
https://www.proquest.com/docview/2758575791
https://www.proquest.com/docview/2761178915
https://pubmed.ncbi.nlm.nih.gov/PMC9806361
https://doaj.org/article/1d9b75146dd846feab811b470e6f4c89
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvY99z1wUPBoOBmD5syXoabWkog5VRWpY3o88lMOwucf7_6hTFbejWJ4Mk27LuzvrpdPodQp8crw2rhMFRXTiuKi-x4sTjUDmlQlQi6hLb57k4u6q-z-pZdritcljl9p-YftSut-Aj_8oA2MpaKvrt-i-GrFGwu5pTaDxG-0BdBlotZ-OCKy78Usa8OEMqLBmZ5V1NIFyCMihiDA6TcsC_d-alRN__L8x5P3TyTvxXmpKmz9GzjCXLo43wX6BHvnuJnvzIu-Wv0MkUjkCtl75cdOX2CGS52kQOln0ohz5ouxhihYEmy7lfRwDbL1wZFWqe6I5eo6vp6eXJGc5JE7CtORuwFNIDRhCN1JWRmnDDpBTCEWO95MzaSlPJLeVO62BrcH5wFSKQMkJaEvgbtNf1nX-HSu20J5Z4VXMfV9HUNMRERGab-KQgHCsQ2Q5ZazOjOCS2-NPSTCJ-b5QL9GW85XpDp_FQ42OQw9gQmLBTQb_83WbDaqlTRkbUJ5yLUCp4bRpKTSWJF6GyjSrQ4VaKbTbPVXurTAX6OFZHw4LdEt35fg1tROxWo2hdoLcboY894UKkiNYCyR112Onqbk23mCfybtVEUCjiez-D4tx26b-jcPDwB7xHTxmcyEheoUO0NyzX_kPESYOZJGOYoP2j6cWvy3g9Pj3_eTFJXocboOEO6g
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgEXxJtAgSCBkJAiHDux4wNCUFht6ePUSnsL8SPsSigp-xDiT_EbmXGSbVeF3nq1J8nEHnu-secB8MqJ3PBMmgTFRSRZ5lWiBfNJnTmtaxSi1IVsn0dyfJJ9neSTLfgzxMKQW-WwJ4aN2rWWzsjfcQK2Klc6_XD6M6GqUXS7OpTQ6MRi3__-hSbb4v3eZ5zf15yPvhzvjpO-qkBic8GXiZLKkxKVhaoyoyomDFdKSseM9Upwa7MqVcKmwlVVbXM6HRC6RqRhpLKsFvjea3AdFS8jY09N1gYeGpqhQh9qZJ0ozib9LSoleKI2auKcglcF4e1zejCUC_gXxr3oqnnO3yyowNEduN1j1_hjJ2x3Ycs39-DGYX87fx92RxRytZr7eNbEQ8hlvOg8FeO2jpdtXdnZEjsMkcynfoWAuZ25GAV4GtIrPYCTKxnOh7DdtI1_DHHlKs8s8zoXHq321BTMIAK0Bb6plo5HwIYhK22fwZwKafwo0z5p-YVRjuDt-pHTLn3HZcSfaB7WhJR5OzS08-9lv5DL1GmjEGVK5xC61b4yRZqaTDEv68wWOoKdYRbLfjtYlGfCG8HLdTcuZLqdqRrfrohGIluFTvMIHnWTvuZESBk8aCNQG-KwwepmTzObhmThukAQKvG7b0hwzlj67yg8ufwHXsDN8fHhQXmwd7T_FG5xigYJJ1I7sL2cr_wzxGhL8zwsjBi-XfVK_AtE30Z7
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3raxQxEB_0CsUv4rtrq64gCMLavDbZfKzVo76KSIv3bcnTO5Ddct37_5vksqdHq_h1M8kOk0nym8wjAK8srTVhXFdBXWjFmBOVpMhVnlkpfVAibFO1z1N-cs4-zepZvnCLuTBZgpdvY1hV4Cht1nF1X1h_mH2Mh-HIk4KgGSExE5Qyfht2GAtG3gR2jqbff5yNe3Ew_dKbebFDFXtkv-aNg2ydTKmA_02o83rw5B8RYOlQmt6DuxlNlkfr6b8Pt1z3AHa_Zn_5QziexiSo1dKVi64ckyDLy3XsYNn7cui9MoshNOhIspy7VYCw_cKWQaXmqeDRIziffjg7PqnyswmVqSkZKsGFiyiBN0IxLRSimgjBuUXaOEGJMUxhQQ2mVilv6nj9QaUPUEpzYZCnj2HS9Z3bg1JZ5ZBBTtbUBTsa6wbpgMlME0by3JIC0Ciy1uSa4vFpi18tzmXEr0m5gDebLhfrghr_In4X52FDGGthpw_98mebl1aLrdQi4D5ubQBT3indYKyZQI57ZhpZwME4i-2oXi2JdpKohcQFvNw0h6UV_SWqc_0q0vDAViNxXcCT9aRvOKGcp5jWAsSWOmyxut3SLeapfLdsAizk4b-vo-L8ZumvUnj635QvYPfb-2n75ePp5324Q2KmRrotOoDJsFy5ZwE_Dfp5XiRXMtwM5Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fracture+in+clinical+studies+of+tofacitinib+in+rheumatoid+arthritis&rft.jtitle=Therapeutic+advances+in+musculoskeletal+disease&rft.au=Hansen%2C+Karen+E&rft.au=Mortezavi%2C+Mahta&rft.au=Nagy%2C+Edward&rft.au=Wang%2C+Cunshan&rft.date=2022-01-01&rft.issn=1759-720X&rft.volume=14&rft.spage=1759720X221142346&rft_id=info:doi/10.1177%2F1759720X221142346&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1759-720X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1759-720X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1759-720X&client=summon